SEARCH RESULTS

1192 RESULTS

CTAD Lessons for 2020: More Phase 2 Trials, More Diversity

CONFERENCE COVERAGE 2020-01-09 Conference Coverage What lies ahead for Alzheimer’s therapy development? While anti-amyloid antibodies are at last signaling some success, researchers agree that these expensive—and, thus far, at best modestly effective—biologic drugs can form only part ...

Tau PET Scans Turn Positive When Amyloid Does; Symptoms Follow

CONFERENCE COVERAGE 2020-01-09 Conference Coverage This article was amended on January 10, 2020 Tau PET is prying open a window on when and where neurofibrillary tangles appear as Alzheimer’s progresses. At the 12th Clinical Trials on Alzheimer’s Disease Conference, held December 4–7 ...

At CTAD, Early Failures and Hints of Success, from Small Trials

CONFERENCE COVERAGE 2019-12-29 Conference Coverage Though Aβ-targeted therapies hogged the limelight at this year’s Clinical Trials on Alzheimer’s Disease meeting, held December 4–7 in San Diego, California, a large handful of smaller studies had findings to report, as well. These ...

Going Indirect: Can Therapies Halt Alzheimer’s from Outside the Brain?

CONFERENCE COVERAGE 2019-12-21 Conference Coverage For therapies taking aim at Alzheimer’s disease, exerting an effect in the brain seems critical. And obvious. But according to results on display at 12th Clinical Trials on Alzheimer’s Disease conference, held December 4–7 in San Diego ...

Picking Through the Rubble, Field Tries to Salvage BACE Inhibitors

CONFERENCE COVERAGE 2019-12-20 Conference Coverage Anti-amyloid antibodies are at long last showing promise for treating Alzheimer’s disease, but for long-term use, researchers are seeking cheaper and easier options than monthly infusions. They want that elusive once-a-day pill. BACE ...

Amyloid Clearance: Check. Cognitive Benefit: Um … Maybe.

CONFERENCE COVERAGE 2019-12-20 Conference Coverage With aducanumab’s resurrection driving renewed interest in anti-amyloid antibody therapies, researchers at the 12th Clinical Trials on Alzheimer’s Disease conference, held December 4–7 in San Diego, happily provided updates on their ...

Blood Tests of Phospho-Tau, Aβ42, Track With Brain Amyloid

CONFERENCE COVERAGE 2019-12-19 Conference Coverage While a suite of new CSF markers has entered a mature stage where they get validated with identical methods in large international cohorts (see previous CTAD story), much newer blood tests are catching up fast. Scientists are pushing ...

Fluid AD Biomarkers Link P-Tau to Synapses, Inflammation

CONFERENCE COVERAGE 2019-12-19 Conference Coverage CSF Aβ42 and phospho-tau may remain the quintessential fluid Alzheimer’s disease biomarkers for now, but a growing cadre of other markers are also proving their worth. At the Clinical Trials on Alzheimer’s Disease conference, held ...

Exposure, Exposure, Exposure? At CTAD, Aducanumab Scientists Make a Case

CONFERENCE COVERAGE 2019-12-13 Conference Coverage There was a new feeling in the air at the 12th Clinical Trials on Alzheimer’s Disease conference. It felt good: After decades of failure, the field might finally be turning a corner. The renewed optimism at the meeting, held December 4 ...

Gene Therapies Enter Trials for Many Brain Pathologies—What about AD?

CONFERENCE COVERAGE 2019-11-28 Conference Coverage Buoyed by success in spinal muscular atrophy, scientists are once again devising gene-based therapies for neurodegeneration. Some are permanent, which makes proving their safety all the more challenging. Still, as shown at this year’s ...

Time to Try Again: Gene-Based Therapy for Neurodegeneration

CONFERENCE COVERAGE 2019-11-27 Conference Coverage Twenty years ago, researchers took fibroblasts from the skin of eight Alzheimer’s patients, engineered them to produce nerve-growth factor, and slid them into each volunteer’s basal forebrain. They hoped the neurotrophin would halt or ...

Not Just Blood Pressure—Dietary Salt Linked to Tau Phosphorylation

CONFERENCE COVERAGE 2019-10-25 Conference Coverage Too much salty food wreaks havoc on the cardiovascular system, raising blood pressure, damaging small blood vessels, and limiting perfusion into the brain. But is this why salt increases the chances of cognitive impairment? Not so fast ...

Can Induced Neurons Identify Early Signs of Neurodegeneration?

CONFERENCE COVERAGE 2019-09-07 Conference Coverage Researchers have linked dozens of genetic loci to late-onset Alzheimer’s disease and found dozens more that cause familial forms of AD and other neurodegenerative diseases. Teasing out how each contributes to pathology has proven a ...

Smart Homes Open Doors to Insights into Aging, Dementia

CONFERENCE COVERAGE 2019-08-30 Conference Coverage Replicating existing paper-and-pencil tests on tablets or smartphones is one thing (Part 13 of this series), but what about taking technology itself to the next level? What are the prospects for continuously collecting information on ...

Technology Brings Dementia Detection to the Home

CONFERENCE COVERAGE 2019-08-30 Conference Coverage The past decade has seen increasing use of technology in dementia research. Computer games that provide cognitive training have become part of prevention studies, and trialists are working to move cognitive testing out of the clinic ...

Current Filters

  • Conference Coverage x
  • TYPE: News x

Remove all filters

Filter By

DATE RANGE
  • All
  • Past 7 Days
  • Past 30 Days
  • Past 90 Days
  • Past 12 Months
  • Specific Dates
    1. From
      To

TYPE
TYPE OF NEWS
DISEASE
TOPIC
BIOMOLECULE